Antengene (HKG:6996) will establish a dedicated artificial intelligence department by increasing its investment in AI-driven drug discovery and AI-focused R&D efforts.
The initiative includes deploying DeepSeek to expedite the development of its next-generation proprietary T-cell engager (TCE) pipeline, which features a steric hindrance-masking technology.
The drugmaker plans to leverage targeted algorithms and AI-driven data mining to perform cross-database, multi-omics analyses for drug discovery and development, a Wednesday bourse filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。